Alzheimer's disease (AD) is a multifactorial neurodegenerative disease which is mainly
characterized by progressive impairment in cognition, emotion, language and memory in …

Alzheimer disease (AD) is the most common form of dementia. The amyloid-β (Aβ) peptide
has become a major therapeutic target in AD on the basis of pathological, biochemical and …

Inflammation is a key pathological hallmark of Alzheimer's disease (AD), although its impact
on disease progression and neurodegeneration remains an area of active investigation …

First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
49447811&utm_source= google_patent&utm_medium= platform_link&utm_campaign …

Background Immunotherapy targeting the amyloid β (Aβ) peptide is a potential strategy to
slow the progression of Alzheimer's disease. We aimed to assess the safety and tolerability …

A61K48/0075—Medicinal preparations containing genetic material which is inserted into
cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of …

Alzheimer's disease is an age-related progressive neurodegenerative disorder with an
enormous unmet medical need. It is the most common form of dementia affecting∼ 5% of …

Aluminum is an experimentally demonstrated neurotoxin and the most commonly used
vaccine adjuvant. Despite almost 90 years of widespread use of aluminum adjuvants …

Amyloid beta (Aβ) immunotherapy for Alzheimer's disease has shown initial success in
mouse models of Alzheimer's disease and in human patients. However, because of …

2014-03-21 Assigned to MODERNA THERAPEUTICS, INC. reassignment MODERNA
THERAPEUTICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR …